Your browser doesn't support javascript.
loading
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro, Alasdair P S; Janani, Leila; Cornelius, Victoria; Aley, Parvinder K; Babbage, Gavin; Baxter, David; Bula, Marcin; Cathie, Katrina; Chatterjee, Krishna; Dodd, Kate; Enever, Yvanne; Gokani, Karishma; Goodman, Anna L; Green, Christopher A; Harndahl, Linda; Haughney, John; Hicks, Alexander; van der Klaauw, Agatha A; Kwok, Jonathan; Lambe, Teresa; Libri, Vincenzo; Llewelyn, Martin J; McGregor, Alastair C; Minassian, Angela M; Moore, Patrick; Mughal, Mehmood; Mujadidi, Yama F; Murira, Jennifer; Osanlou, Orod; Osanlou, Rostam; Owens, Daniel R; Pacurar, Mihaela; Palfreeman, Adrian; Pan, Daniel; Rampling, Tommy; Regan, Karen; Saich, Stephen; Salkeld, Jo; Saralaya, Dinesh; Sharma, Sunil; Sheridan, Ray; Sturdy, Ann; Thomson, Emma C; Todd, Shirley; Twelves, Chris; Read, Robert C; Charlton, Sue; Hallis, Bassam; Ramsay, Mary; Andrews, Nick.
Afiliação
  • Munro APS; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
  • Janani L; Imperial Clinical Trials Unit, Imperial College London, London, UK.
  • Cornelius V; Imperial Clinical Trials Unit, Imperial College London, London, UK.
  • Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Babbage G; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Baxter D; Stockport NHS Foundation Trust, Stockport, UK.
  • Bula M; NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
  • Cathie K; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
  • Chatterjee K; NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Dodd K; NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
  • Enever Y; PHARMExcel, Welwyn Garden City, Hertfordshire, UK.
  • Gokani K; NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Goodman AL; Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
  • Green CA; NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Harndahl L; Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
  • Haughney J; Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK.
  • Hicks A; Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
  • van der Klaauw AA; Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK.
  • Kwok J; Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK.
  • Lambe T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
  • Llewelyn MJ; University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
  • McGregor AC; Department of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK.
  • Minassian AM; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Moore P; The Adam Practice, Poole, UK.
  • Mughal M; Stockport NHS Foundation Trust, Stockport, UK.
  • Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Murira J; NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
  • Osanlou O; North Wales Clinical Research Facility, Betsi Cadwaladr University Health Board and Bangor University, Bangor, UK.
  • Osanlou R; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Owens DR; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
  • Pacurar M; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
  • Palfreeman A; University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK.
  • Pan D; University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK.
  • Rampling T; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
  • Regan K; Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
  • Saich S; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Salkeld J; Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Saralaya D; Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
  • Sharma S; University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
  • Sheridan R; Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
  • Sturdy A; Department of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK.
  • Thomson EC; Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK; MRC University of Glasgow Centre for Virus Research, Glasgow, UK.
  • Todd S; Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
  • Twelves C; NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
  • Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
  • Charlton S; UK Health Security Agency, Porton Down, UK.
  • Hallis B; UK Health Security Agency, Porton Down, UK.
  • Ramsay M; UK Health Security Agency, Colindale, London, UK.
  • Andrews N; UK Health Security Agency, Colindale, London, UK.
Lancet ; 398(10318): 2258-2276, 2021 12 18.
Article em En | MEDLINE | ID: mdl-34863358

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunização Secundária / Imunogenicidade da Vacina / COVID-19 / Vacina BNT162 / ChAdOx1 nCoV-19 Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunização Secundária / Imunogenicidade da Vacina / COVID-19 / Vacina BNT162 / ChAdOx1 nCoV-19 Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido